Across TCGA pan-cancer cohorts, HLA-DRB1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated HLA-DRB1 data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in acute myeloid leukemia (LAML), where higher HLA-DRB1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HLA-DRB1 expression acts as an unfavorable survival marker.

LAML and SCLC are the cancer types where HLA-DRB1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LAML	DFS	Median	All	0.028	0.572	<.001	12	view →
SCLC	OS	Median	All	0.082	0.822	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: HLA-DRB1 tumor-vs-normal RNA expression · all HLA-DRB1 data types